Rupatadine is a modern non-sedating H1-antihistamine that also haswith additional antagonist e ects on platelet-activating factor (PAF). Under the tradenames Rupa n® and Urtimed®, Rrupatadine is approvedregistered in Germany for the treatment of allergic rhinitis and urticaria infor adults and children aged over 12 years. In this review, the available literature available to date onregarding the pharmacological pro le and clinical application of Rrupatadine is reviewed and compared to other conventional histamines. In conclusionFinally, the side e ects, safety and interaction pro leincompatibility of Rrupatadine are discussed. Due to CYP p450 metabolism, Rrupatadine should not be given together with Eerythromycin, Kketoconazole or grapefruit juice. Rupatadine has been found to be e ective and safe Iin a variety of randomized clinical trials both in both seasonal and perennial allergic rhinitis, as well as inbut also chronic urticaria Rupatadine has been found as e ective and safe.
Introduction
More than 45 H1 antihistamines (H1 histamine receptor antagonists), forming the largest class of drugs for the treatment of allergic diseases, are available worldwide [1] . Despite comparable e cacy in the treatment of allergic rhinoconjunctivitis, urticaria and other allergic diseases, approved preparations di er in terms of their chemical structure, clinical pharmacology and potential toxicity.
Rupatadine is a novel substance which, in addition to being an H1 antagonist, is also a potent platelet-activating factor (PAF) inhibitor. It belongs to the N-alkyl pyridine derivates. Animal and human models [2] have shown rupatadine to have dual antihistamine and PAF-antagonist properties. It is commercially available in Spain as 10-mg tablets and has already been approved in several other Euro pean countries [3, 4] . Rupatadine has been available in Germany for the treatment of allergic rhinitis and chronic urticaria in adults and children aged over 12 years under the tradename Rupa n® 10 mg since August 1, 2008 , and under the tradename Urtimed® since 2010 [5] . e present article discusses the pharmacology, kinetics, anti-in ammatory e ects, clinical e cacy as well as the side effects and interaction pro le of this antihistamine.
Pharmacology and kinetics
Rupatadine (8-chloro-11-[1-[(5-methyl-3-pyridinyl) methyl]piperidin-4-ylidene]-6,11-dihydro-5H-benzo [5, 6] cyclohepta [1,2-b] pyridine fumarate), a second-generation antihistamine, is a selective, longacting histamine antagonist with peripheral H1 receptor activity (Fig. 1) [2] . Desloratadine and its hydroxylated metabolites are some of the rupatadine metabolites that may contribute to the drug's overall e cacy [5] .
In vitro metabolism studies using human liver microsomes show that the cytochrome P450 CYP3A4 is the isoenzyme primarily responsible for the biotransformation of rupatadine [5, 6] .
e time to maximum plasma concentration (T max ) in adults is between 45 min and 1 h following oral intake (Tab. 1). e drug's half-life is 5.9 h. Rupatadine undergoes signi cant presystemic metabolism when administered orally. e most important biotransformation pathways of rupatadine include oxidative processes, oxidation of the pyr-idine-methyl group to carboxylic acid, N-dealkylation of piperidine nitrogen and hydroxylation of the 3-, 5-and 6-positions in the tricyclic ring system [7] . Only insigni cant amounts of unaltered active substance were found in urine and feces [4, 5, 8, 9] . e pharmacokinetics of rupatadine are linear for doses between 10 mg and 40 mg [5, 8] .
e binding rate of rupatadine to plasma protein is 98 %-99 %. Despite this high binding rate, it is well distributed and is able to reach target receptors [6] .
Studies have shown that the active substance's maximum plasma concentration is delayed by approximately 1 h when taken with food; despite this delay, the maximum concentration in blood remained unaltered by food intake [5, 8] .
Anti-in ammatory and antihistaminergic e ects of rupatadine
Rupatadine has a high a nity for the H1 receptor.
is activity has been demonstrated in vitro and in a broad spectrum of pharmacological in vivo models in mice, rats, guinea pigs, rabbits, dogs and humans.
Rupatadine inhibits histamine-induced guinea pig ileum contraction at concentrations in the nanomolar range [2] . is ability has been compared in several studies with data on already established antihistamines such as loratadine or terfenadine [8] .
e dissociation constant Ki for the three antihistamines was 102, 127 and 144 nM. e same model showed that rupatadine is better than loratadine and fexofenadine at suppressing 3H-mepyramina radioligand for the histochemical investigation of histamine receptors -from its H1 binding site (shown in Tab. 2 as the mean inhibitory concentration IC50) [2] . Rupatadine shows strong selectivity for binding to lung-tissue H1 receptors compared to brain (cerebellum) H1 receptors following oral administration of 0.16 mg/kg in guinea pigs. Similar ndings have been reported for loratadine, whilst hydroxyzine showed no di erentiation between lung and brain and diphenhydramine blocked lung receptors only weakly (< 10 %) [8] .
Abbreviations used
Merlos and co-workers [2] were also able to show that rupatadine has a selective e ect on histamine H1 receptors; however, no e ects on acetylcholine, serotonin or leukotriene receptors were observed.
e intensity and duration of inhibition of wheal and erythema formation in the histamine skin prick model increases with dose escalation, reaching peak values of 69 %, 82 % and 93 % following doses of 10, 20 and 40 mg, respectively [9] .
Rupatadine's antihistamine activity has been investigated in a number of in vitro models (Tab. 2) [2] .
PAF antagonist activity
PAF is an endogenous phospholipid mediator of inammation made up of in ammatory cells such as alveolar macrophages, eosinophils, mast cells, basophils, platelets and neutrophils, which are released in response to allergic/in ammatory reactions.
ese reactions are associated with increased vascular permeability, eosinophil chemoattraction, bronchoconstriction and airway hyperresponsiveness, all of which are involved in the pathophysiology of rhinitis, asthma and anaphylaxis. Moreover, increased plasma levels of PAF have been reported in patients with urticaria and psoriasis compared with healthy controls [10, 11, 12] .
Rupatadine demonstrates competitive PAF antagonistic activity in the submicromolar range in vitro, with IC50 values of 0.2 and 0.68 µM in models to evaluate thrombocyte aggregation in washed thrombocytes from rabbit or human platelet-rich plasma, respectively. In these models, rupatadine's anti-PAF activity was lower than the speci c PAF antagonists WEB-2086 and Ginkgolid B, but significantly higher than that of the antihistamines loratadine, ketotifen, mepyramine, cetirizine or terfenadine [8] .
e dose-response relationship of rupatadine in the inhibition of PAF-induced wheals and erythema is shown in Tab. 3 [9] . e e cacy of rupatadine increases in a linear fashion at increasing doses up to 40 mg; beyond this dose, dose escalation is associated with a slower increase in e cacy [7] .
Church [13] showed rupatadine to have long-lasting e cacy at four times the recommended dose over up to 72 h against PAF-induced dermal ares following skin prick testing. 
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Anticholinergic e ects
In contrast to many other rst-generation antihistamines, no anticholinergic e ects were observed for single doses of rupatadine in the 10-to 80-mg dose range [7] .
Other antiin ammatory/antiallergic e ects
Several studies have con rmed that rupatadine exhibits inhibitory e ects, e. g. on mast cell degranulation and eosinophil chemotaxis, in various type-1 hypersensitivity models. Rupatadine blocks isolated mast cell degranulation in sensitized dogs. In this particular model, the e ects of rupatadine were comparable to those of loratadine, although rupatadine tends to achieve a greater overall e ect [4, 8, 14, 15, 16] .
In addition to histamine, it was also possible to inhibit the release of LTC4 from peritoneal rat mast cells, as well as the release of tumor necrosis factor (TNF)-α from human mast cell lines. It has been suggested that this property may play a bene cial role in the late phase of allergic reactions [7, 17, 18, 19] .
Barrón et al. [20] demonstrated that, at concentrations of between 10 and 100 nM, rupatadine inhibits human eotaxininduced eosinophil chemotaxis.
Rupatadine also inhibits PAF-and LTB4-induced human neutrophil chemotaxis. In Ramis et al.'s model, rupatadine was shown to be more e ective than other antihistamines, such as cetirizine, fexofenadine, loratadine and mizolastine [21] .
e inhibitory e ects of a number of antihistamines (rupatadine, desloratadine, levocetirizine and fexofenadine) on proin ammatory cytokine (interleukin [IL-6] and IL-8) secretion were investigated in human umbilical venous endothelial cells (HUVEC) activated by histamine. Rupatadine showed the lowest IC50 value, followed by desloratadine, levocetirizine and fexofenadine [22] .
Furthermore, several studies observed inhibition of: secretion of other lymphocyte cytokines (IL-5, IL-6, IL-8, granulocyte macrophage colony-stimulating factor [GM-CSF] and TNF-α), as well as expression of allergy-associated adhesion molecules (CD18 and CD11b) and various transcription factors (nuclear factor κ-light-chain-enhancer of activated B-cells, NF-κB) [8] .
Clinical studies
The majority of available studies still subdivide allergic rhinitis according to the older system into seasonal (SAR) and perennial allergic rhinitis (PAR), whilst only a small number refer to the new ARIA (allergic rhinitis and its impact on asthma) criteria, which classify allergic rhinitis into intermittent or persistent allergic rhinitis [23, 24, 25] .
Interestingly, many authors observed a fast onset of action in patients with SAR, PAR, persistent allergic rhinitis (PER ) and chronic idiopathic urticaria in clinical studies on rupatadine. ese observations are consistent with the drug's pharmacokinetic pro le [7, 8, 13] .
Seasonal allergic rhinitis
Clinical studies on rupatadine in patients with moderate to severe SAR are summarized in Tab. 4. e Review Article E cacy and safety of rupatadine Übersicht results of these studies con rm the e cacy of rupatadine to reduce mean daily total symptom scores (mDTSS). Covariate analysis found no age-or sexspeci c di erences. All rupatadine doses investigated were more effective at reducing SAR symptoms in a dose-dependent manner than placebo. Two studies measured the objective e cacy of rupatadine 10 mg in the reduction of nasal obstruction following allergen provocation; here again, rupatadine was signi cantly superior to placebo [26, 27] .
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Overall, doses of 10 mg and 20 mg were the most e ective compared to lower doses and, apart from a general trend towards faster symptom relief at 20 mg, signi cant di erences following 1-week treatment were observed [7, 28] .
Rupatadine 10 mg once daily was compared with ebastine 10 mg once daily and placebo [29] . A er 2 weeks, mDTSS values in the rupatadine group were 33 % lower than placebo (p = 0.005). e total symptom score for rupatadine was 22 % lower compared with ebastine; however, this result did not reach statistical signi cance. Compared with placebo, rupatadine reduced all symptoms with a statistically signi cant reduction of sneezing, rhinorrhea, lacrimation and nasal itch. e greatest di erence between active treatment and placebo was observed for rhinorrhea (rupatadine vs. placebo, p < 0.001; ebastine vs. placebo, p < 0.005). e e cacy of rupatadine and levocetirizine was compared for 2 weeks in SAR patients [30] . A signicantly greater reduction (p = 0.004) in immunoglobulin-E (IgE) levels and overall nasal symptom scores (p < 0.001) was observed in the rupatadine group compared with the levocetirizine group. ere was an 18.08 % (p = 0.02) reduction in the score for the rhinoconjunctivitis quality of life questionnaire (RQLQ) in the rupatadine group, a signi cantly greater reduction than that seen in the levocetirizine group.
Several studies comparing the 10-and 20-mg doses of rupatadine with the approved daily doses of cetirizine and loratadine showed rupatadine to be bene cial [31, 32, 33] .
In a newly published study, the e cacy of rupatadine and olopatadine was compared in SAR patients [34] . e olopatadine group showed a signi cantly greater reduction in serum IgE values (p = 0.01), total nasal symptoms scores (p < 0.001) and RQLQ scores (p = 0.015) compared to rupatadine.
Perennial allergic rhinitis
Rupatadine at doses of 10 or 20 mg once daily was signi cantly superior to placebo in the treatment of PAR [35] .
Compared with other antihistamines, rupatadine proved to be at least as e ective as cetirizine, ebastine and loratadine for the relief of nasal and ocular symptoms in patients with PAR [35, 36] . Table 4 Summary of e cacy of rupatadine in adults and adolescents (> 12 years) with seasonal allergic rhinitis (SAR) 
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Study
Persistent allergic rhinitis
A small number of studies and analyses investigated the clinical e cacy and tolerability of rupatadine in PER according to the new ARIA classi cation [23, 24, 25, 37, 38] . ere was a marked improvement in quality of life under rupatadine therapy, 10 mg once daily, compared to placebo. e same bene cial effect was also observed for 10-mg cetirizine.
Results from the Futura study [38] showed that, with the exception of nasal congestion and secretion, which improved only a er the second day of treatment (p < 0.001), all symptoms improved markedly in the rst days of treatment (p < 0.001).
Chronic urticaria
Several studies have evaluated the e cacy of rupatadine in chronic urticaria patients. e two most relevant scores in the evaluation of chronic urticaria, the mean pruritus severity score (MPS) and the mean number of wheals score (MNW), could be signi cantly reduced. ere was a clear di erence in favour of rupatadine 10 and 20 mg compared to placebo (p = 0.013 and p < 0.0001) following the rst dose. Of particular note is rupatadine's fast onset of action [39, 40, 41] .
When evaluated in terms of the dermatology life quality index (DLQI), rupatadine again proved to be signi cantly superior compared with placebo [40] . e e cacy of rupatadine and levocetirizine in chronic urticaria was compared over a 4-week period [42] . By day 28, rupatadine had produced a marked improvement in clinical status and symptom score compared with initial values. e rupatadine group showed a reduction in serum IgE of 15.3% (p = 0.024), a drop in total symptom score of 28.2% (p = 0.02) and a reduction in the speci c quality of life questionnaire score of 27.3 % [43] . e overall e cacy score for rupatadine was signi cantly higher (p = 0.009) compared to levocetirizine.
Rupatadine also proved to be e ective in the treatment of cold urticaria [44] .
Tolerability and safety
Results from the clinical phase-III study carried out by Picado et al. [45] in a total of 3490 patients or healthy volunteers are summarized in Tab. 5.
In a multicenter phase-IV study, 120 PER patients were treated with rupatadine for 12 months to evaluate the substance's long-term safety in accordance with guidelines of the European Medicines Agency (EMEA) [46, 47] . In par-ticular, headache, drowsiness and dry mouth were the most commonly observed side e ects. No clinically relevant changes in electrocardiogram (ECG) were observed. is study con rms rupatadine's good long-term safety pro le.
One case of xed drug eruption was attributed to rupatadine and con rmed by oral provocation testing [48] .
Cardiac toxicity
A number of older antihistamines, such as astemizole and later terfenadine, are known to cause prolongation of the QT interval by direct blockade of repolarizing potassium channels, thereby increasing the risk of torsades de pointes arrhythmias [49] [50]. However, these e ects are not related to interaction with speci c H1 receptors and, as such, are not histamine-speci c [8, 51] .
e cardiac safety of rupatadine has been extensively and repeatedly investigated in clinical studies [4, 45, 52] .
Preclinical studies yielded the following results: -Rupatadine doses 100 times that of the clinically recommended dose of 10 mg had no e ect whatsoever on ECG parameters, blood pressure or pulse rate in rats, guinea pigs and dogs. No arrhythmias or other cardiovascular complications were observed [53] . -Concentrations of rupatadine and one of its most important metabolites in humans (3-hydroxydesloratadine) exceeding at least 2000-fold the C max value (C max : maximum plasma concentration) reached a er the administration of a 10-mg dose in humans had no e ect on the cardiac action potential in in vitro isolated canine Purkinje bers [5, 7, 8 ]. -In a study designed to investigate the e ect on a cloned human ether-a-go-go related gene (HERG) potassium channel, the channel was blocked by rupatadine at a concentration 1685 times greater than the C max value reached following administration of max value reached following administration of max 10 mg rupatadine. Tissue distribution studies using radiolabeled rupatadine in rat tissue showed no accumulation of rupatadine in heart tissue [5, 7, 8] . -A QT/QTc study was carried out In line with the guideline recommendations of the EMEA and the Review Article E cacy and safety of rupatadine
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Übersicht
International Conference on Harmonisation (ICH) E14. In the positive control group, moxioxacin demonstrated the expected changes in QTc interval. ECG data for rupatadine at 10 and 100 mg showed no e ects. ere were no sex-speci c e ects and no pharmacodynamic link between rupatadine and its main metabolites, thereby con rming that rupatadine has no particular e ect whatsoever on QTc interval. is study demonstrated that rupatadine has no proarrhythmic side e ects even at 10 times the therapeutic dose [5, 7, 8] .
Central nervous system toxicity
Rupatidine behaves like other second-generation antihistamines and is non-sedating. Even doses as high as 100 mg/kg in a series of tests in rats and mice failed to produce changes in ECG or motor activity [2, 54] .
No psychomotor impairment could be detected in humans at doses of up 20 mg. However, dosedependent impairments were seen at higher doses. Hydroxyzine 25 mg (p = 0.01) and rupatadine 80 mg (p = 0.02) produced signi cant impairment of similar degree. e cognitive and psychomotor impairment produced by a single 10-mg oral dose of rupatadine in combination with ethanol was no greater than the impairment produced by ethanol alone, whilst a higher dose (20 mg) in combination with ethanol caused cognitive and psychomotor impairment comparable to that seen with hydroxyzine 25 mg and cetirizine even at therapeutic doses [55, 56] . e e ects of rupatadine on tness to drive were investigated in a study on healthy subjects: at the recommended dose of 10 mg rupatadine, no di erences could be seen compared to placebo [3, 57] .
Drug interactions
Simultaneous administration of 20 mg rupatadine and ketoconazole or erythromycin (or any other potential CYP3A4 inhibitor) increases systemic rupatadine exposure (as measured by the area under the concentration time curve, AUC) by 10-and two-to three-fold, respectively. ese changes were not associated with any e ect on the QT interval or an increase in side e ects.
Rupatadine is well tolerated in combination with azithromycin or uoxetine and can be administered in therapeutic doses without risk [5, 7, 8] .
Simultaneous intake of grapefruit juice increased rupatadine exposure 3.5-fold. When administering a four times higher dose of rupatadine, as recommended for the treatment of urticaria [13] , together with grapefruit juice, rupatadine exposure may increase more than 10-fold, thereby exceeding the QT/ QTc study conditions which, even at a dose of 100 mg, produced no changes in QTc interval. It was possibly potential summation e ects of this kind that prompted the manufacturers to contraindicate co-administration of rupatadine 10-mg tablets and grapefruit juice.
Food intake increased systemic rupatadine exposure by 23 %; however, exposure to its metabolites remained una ected.
e time to rupatadine's peak plasma concentration (T max tion (T max tion (T ) was delayed by 1 h, whilst the C max was max was max una ected. ese di erences were of no clinical signi cance [5, 7, 8] .
Elderly patients: peak concentration and AUC values for rupatadine are higher in elderly patients than in young adults. Similarly, the mean plasma half-life (t1/2) is 8.7 h compared to 5.9
Conclusion
Rupatadine is a relatively new substance with potent histamine H1 and PAF antagonist activity. It is approved in Germany under the tradenames Rupa n® and Urtimed® 10 mg for the treatment of allergic rhinitis and chronic urticaria in adults and children aged over 12 years.
In addition to its powerful and selective H1 antihistamine activity, rupatadine acts primarily as a PAF antagonist. e drug also has other antiin ammatory e ects, such as inhibition of mast cell granulation and eosinophil chemotaxis.
Studies have con rmed the clinical e cacy of rupatadine. At the same time, numerous clinical trials of the drug demonstrated its fast onset of action in patients with SAR, PAR, PER and chronic idiopathic urticaria.
Several studies were able to show that 10-and 20-mg doses of rupatadine were equal or superior to the approved daily doses of cetirizine and loratadine in terms of reducing mean daily total symptom scores.
At doses of 10-20 mg once daily, rupatadine proved to be highly e ective in the treatment of chronic urticaria.
Rupatadine has a good safety pro le. Isolated reports of side e ects include headache or fatigue. No clinically relevant changes were seen on ECG. No psychomotor e ects could be seen in humans at doses of up to 20 mg. Rupatadine does not impair driving performance.
Co-administration of rupatadine with erythromycin, ketoconazole and grapefruit should be avoided.
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